#### **ORIGINAL ARTICLE**



# The effectiveness and safety of annulus closure device implantation in lumbar discectomy for patients with lumbar disc herniation: a systematic review and meta-analysis

Wei-Shang Li<sup>1</sup> · Gao-Yu Li<sup>2</sup> · Qi Yan<sup>3</sup> · Wen-Ting Chen<sup>4</sup> · Lin Cong<sup>1</sup>

Received: 9 December 2022 / Revised: 22 February 2023 / Accepted: 23 February 2023 / Published online: 3 April 2023 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

## Abstract

**Objective** The objective of this study was to systematically estimate the effectiveness and safety of annulus closure device (ACD) implantation in discectomy for patients with lumbar disc herniation (LDH).

**Methods** A systematic search was performed on PubMed, EMBASE and the Cochrane Library for randomized controlled trial (RCT) from inception until April 16, 2022. Trials which investigated comparisons between with and without ACD implantation in discectomy for LDH patients were identified.

**Results** In total, five RCTs involving 2380 patients with LDH underwent discectomy were included. The included patients were divided into ACD group and control group (CTL). Significant differences were found in the rate of re-herniation (ACD: 7.40%, CTL: 17.58%), reoperation (ACD: 5.39%, CTL: 13.58%) and serious adverse event (ACD: 10.79%, CTL: 17.14%) between ACD group and CTL group. No significant difference was found in VAS-BACK, VAS-LEG, ODI and SF-12 PCS between ACD and CTL. The surgical time of ACD was longer than CTL with statistical significance. In subgroup analyses based on discectomy type, significant differences were found in the rate of re-herniation (ACD: 10.73%, CTL: 21.27%), reoperation (ACD: 4.96%, CTL: 13.82%) and serious adverse event (ACD: 7.59%, CTL: 16.89%) between ACD and CTL in limited lumbar discectomy (LLD).

**Conclusion** Discectomy either with or without ACD implantation is considered to achieve similar clinical outcomes. Whereas, the ACD implantation in LLD is associated with lower re-herniation and reoperation rate but prolonged surgical time for LDH patients. Researches on cost-effectiveness and effect of ACD implantation in different discectomy are needed in the future.

- - -

Keywords Annulus closure device · Discectomy · Lumbar disc herniation · Meta-analysis · Systematic review

We	Wei-Shang Li and Gao-Yu Li have contributed equally to this work.								
	Lin Cong chinaconglin@outlook.com								
1	Department of Orthopedic Surgery, The First Hospital of China Medical University, No.155, Nanjing Bei Street, Shenyang 110001, People's Republic of China								
2	Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No.36, Sanhao Street, Shenyang 110001, People's Republic of China								
3	Departments of Surgery, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7741, San Antonio, TX 78229-3900, USA								
4	Disease Control and Prevention Center of China Railway Shenyang Bureau Group Corporation, No.4, Taiyuan Bei Street, Shenyang 110001, People's Republic of China								

Abbreviatio	ons
ACD	Annulus closure device
LDH	Lumbar disc herniation
LLD	Limited lumbar discectomy
SCIE	Science citation index expanded
WoS	Web of Science
PRISMA	Preferred reporting items for systematic
	reviews and meta-analyses
RCT	Randomized controlled trial
MED	Micro-endoscopic discectomy
PED	Percutaneous endoscopic discectomy
UBE	Unilateral biportal endoscopic discectomy
VAS	Visual analogue scale
SEA	Serious adverse event
ODI	Oswestry disability index
SF-12 PCS	Physical component summary of 12-item
	short-form health survey
MD	Mean difference

95% CI	95% Confidence interval
OR	Odds ratio
ALD	Aggressive lumbar discectomy
VEPC	Vertebral endplate changes
NA	Not available
Exp	Experimental group
CTL	Control group

## Introduction

Since Mixter and Barr have first reported the surgical treatment for symptomatic lumbar disc herniation (LDH) in 1934 [1], discectomy is regarded as major treatment of symptomatic LDH. With the continuous advancement of minimally invasive surgery, various surgical approaches for lumbar discectomy have been invented and proposed, such as micro-discectomy, micro-endoscopic discectomy (MED), percutaneous endoscopic discectomy (PED), full-endoscopic discectomy (UBE) [2–6]. Whereas, the problems of postoperative re-herniation and reoperation have not been solved [7, 8], which has become a consensus of high cost and poor prognosis [9, 10]. Therefore, the reduction of recurrence rate and reoperation rate has always been a research hotspot [11].

A study reported that postoperative re-herniation could be related to annular defects due to lumbar discectomy [12]. Moreover, Miller et al. [13] suggested that patients with large postoperative annular defects ( $\geq 6 \text{ mm width}$ ) had a 2.5-fold higher rate of re-herniation, compared with patients who had small annular defects (<6 mm width) after discectomy. Hence, repairing annular defects to reduce the re-herniation rate and reoperation rate has been proposed in recent years, which was performed by implantation of an annular closure device (ACD)-Barricaid<sup>TM</sup> (Intrinsic Therapeutics, Inc., Woburn, MA, USA) or Xclose Tissue Repair System (Anulex Technologies, Minnetonka, MN) [14, 15]. Many clinical studies have been published focusing on their effectiveness. Some trials suggested that implantation of ACD resulted in better clinical outcomes [16, 17] and reduced the risk of symptomatic re-herniation and reoperation [18-20]. However, Bailey et al. [14] held different opinions, suggesting that the differences of re-herniation rate between groups at all follow-up time points were not statistically significant in their study. Considering the effect of these devices for preventing re-herniation remained controversial among individual studies, we performed this study to systematically estimate the effectiveness and safety of ACD implantation in lumbar discectomy for patients with LDH.

## **Materials and methods**

#### **Protocol and registration**

The review protocol of this study was prospectively registered (PROSPERO, CRD42022309101), following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and checklist.

#### Search methods and selection criteria

We performed a systematic search on PubMed, EMBASE and the Cochrane Library for randomized controlled trials (RCTs) from inception until April 16, 2022. Trials compared lumbar disc herniation (LDH) patients who underwent discectomy with and without implantation of ACD were identified. Keywords were used as annulus closure device, discectomy and lumbar disc herniation.

The selection criteria for including RCTs in this study were shown as follows: (1) performed the comparison between patients with LDH that underwent discectomy with and without the implantation of ACD; (2) participants were adults who suffer symptomatic LDH; (3) contained at least one outcome of interest. RCTs were excluded if: Interventions were different from the previous description; Or original data were not available.

#### Data extraction and statistical analyses

Two researchers extracted the data for meta-analysis independently. Description and outcomes of included trials were checked carefully. The primary outcomes were the rates of re-herniation and reoperation between ACD group and control (CTL) group. Secondary outcomes were visual analogue scale (VAS), oswestry disability index (ODI), physical component summary of 12-item shortform health survey (SF-12 PCS), surgical time and serious adverse event (SAE) between ACD group and CTL group. To compare the different effect of ACD between surgical techniques more precisely, subgroup analyses were performed based on the surgery type. Mean difference (MD) and 95% confidence interval (CI) were used for presenting the continuous outcomes. Dichotomous outcomes were presented by odds ratio (OR) and 95% CI. RevMan software (version 5.3) was used to perform all analyses. Between-study heterogeneity was evaluated using chi-squared test and  $I^2$ . If the P value was < 0.05, statistical heterogeneity exists. In this situation, a randomeffects model was utilized. P < 0.05 was considered to be statistically significant.

#### Assessment of risk of bias

The Cochrane Collaboration's risk of bias criteria were used to evaluated the risk of bias in each included trial. The classifications of bias were based on seven items: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. Each item was rated as low risk, unclear risk, or high risk.

## Results

#### Study selection and characteristics

A total of 358 unique records were retrieved yielding 143 studies after removing duplications. One hundred and thirty studies were excluded according to the title and abstract screening. After removing duplications and full-text screening, eight trials were eliminated yielding five trials meeting 2379

the inclusion criteria for meta-analysis in this study (Fig. 1). The description and outcomes of all included trials are shown in Table 1. Five trials involving 2380 patients with symptomatic LDH underwent discectomy were included in this study [14, 21–24]. The sample size in these trials ranged from 60 to 727. All included trials contained explicit inclusion and exclusion criteria. Four trials performed discectomy with the implantation of bone-anchored annular closure device and one trials used Xclose Tissue Repair System as annular closure device. Three trials performed limited lumbar discectomy (LLD) and one trial performed limited micro-discectomy. The other trial reported that investigators performed discectomies per their standard practice, conducting with standard or tubular retractors, with or without use of an operating microscope or loupes.

#### **Meta-analysis results**

Significant differences were found in the rate of re-herniation (ACD: 7.40%, CTL: 17.58%; OR: 0.43; 95% CI [0.31, 0.58],  $P < 0.001, l^2 = 0\%$ ), reoperation (ACD: 5.39%, CTL: 13.58%; OR: 0.36; 95% CI [0.24, 0.53],  $P < 0.001, l^2 = 0\%$ ) and SAE



Table 1 Characteristics of the included trials

Trial	Sample size (Exp/ Clt)	Mean age (Year, Exp/ Clt)	Male (%, Exp/Clt)	Closure device type	Outcomes
Bailey 2013 [14]	478/249	42.4/41.9	59.4/56.2	Xclose tissue repair system	VAS, ODI, SF-12 PCS, re- herniation, reoperation
Barth 2018 [21]	242/251	42.9/44.0	61.4/58.7	Bone-anchored annular closure device	VAS, ODI, surgical time
Cho 2019 [22]	30/30	41.4/42.6	66.7/83.3	Bone-anchored annular closure device	VAS, ODI, SF-12 PCS, surgical time, re-herniation, reopera- tion
Kuršumović 2018 [23]	267/283	43.0/44.0	58.1/60.8	Bone-anchored annular closure device	Re-herniation, reoperation
Thomé 2018 [24]	272/278	43.0/44.0	57.0/62.0	Bone-anchored annular closure device	VAS, ODI, re-herniation, reop- eration

VAS visual analog scale, ODI oswestry disability index, SF-12 PCS physical component summary of 12-item short-form health survey, NA not available, Exp experimental group, and Clt control group

(ACD: 10.79%, CTL: 17.14%; OR: 0.52; 95% CI [0.33, 0.83], P = 0.006,  $I^2 = 60\%$ ) between ACD group and CTL group at 24 months after surgery (Fig. 2). No significant difference was found in VAS-leg (MD, -0.23 [95% CI -0.69 to 0.23], P = 0.33,  $I^2 = 0\%$ ) and VAS-back (MD, -0.14 [95% CI -0.60 to 0.33], P = 0.56,  $I^2 = 0\%$ ) (Fig. 3). No statistical significance was found in SF-12 PCS (MD, -0.56 [95% CI -2.10 to 0.98], P = 0.48,  $I^2 = 0\%$ ) between ACD group and CTL group, and the surgical time of ACD group was longer than CTL group with statistical significance (MD, 18.11 [95% CI 13.50 to 22.72], P < 0.001,  $I^2 = 0\%$ ) (Fig. 3). There was no significant difference between ACD group and CTL group in ODI (MD, 0.59 [95% CI -1.85 to 3.03], P = 0.64,  $I^2 = 52\%$ ) (Fig. 3).

#### Subgroup analysis results

In subgroup analyses based on the surgery type, significant differences were found in the rate of re-herniation (ACD: 10.73%, CTL: 21.27%; OR: 0.44; 95% CI [0.31, 0.63], P < 0.001,  $I^2 = 0\%$ ), reoperation (ACD: 4.96%, CTL: 13.82%; OR: 0.33; 95% CI [0.21, 0.51], P < 0.001,  $I^2 = 0\%$ ) and SAE (ACD: 7.59%, CTL: 16.89%; OR: 0.40; 95% CI [0.27, 0.60], P < 0.001,  $I^2 = 0\%$ ) between ACD group and CTL group at 24 months after LLD (Fig. 4). The frequency of vertebral endplate changes in ACD group was superior to CTL group at 24 months after LLD (OR: 11.85; 95% CI [8.83, 15.90], P < 0.001,  $I^2 = 0\%$ ) (Fig. 4).

## **Risk of bias**

The risk of bias in each included trial was evaluated following the Cochrane Collaboration's risk of bias criteria. The appropriate random sequence generation was reported in all five trials and the allocation concealment in four trials [14, 21–24]. One trial was double-blind randomized controlled trial where surgeons and participants were blinded [22]. Trial of Bailey et al. [14] failed in blinding of outcome assessment. There was an industry funding in three trials [21, 23, 24], which was the reason that the other bias was unclear risk (Fig. 5).

## Discussion

The re-herniation rate (ACD: 7.40%, CTL: 17.58%) and reoperation rate (ACD: 5.39%, CTL: 13.58%) of ACD group were lower than CTL group with statistical significance at 24 months after surgery. Moreover, we performed a series of subgroup analyses based on surgery type. After discectomy was first reported as a surgical treatment for symptomatic LDH in 1934, O'Connell described an aggressive method for removing intervertebral disc, namely aggressive lumbar discectomy (ALD) [25]. ALD included removing the herniated disc fragment and scaling the remaining disc. Another method for disc removal described by Spengler and Williams emphasized removing the herniated disc alone without invasion of the disc space, namely LLD [26, 27]. LLD and ALD are both commonly used in clinical practice and have their own disadvantages. McGirt et al. [28] suggested that LLD was associated with lower incidence of long-term recurrent back pain but a higher incidence of re-herniation compared with ALD. In this presenting study, three trials performed LLD and one trial performed limited micro-discectomy [21-24]. The trial by Bailey et al. [14] reported that investigators performed discectomies per their standard practice, conducting with standard or tubular retractors, with or without use of an operating microscope or loupes. Sensitivity analysis showed that the data by Bailey et al. had no effect on the results. Moreover, the results of subgroup



Heterogeneity: Tau<sup>2</sup> = 0.10; Chi<sup>2</sup> = 5.01, df = 2 (P = 0.08);  $I^2 = 60\%$ 

Test for overall effect: Z = 2.76 (P = 0.006)

Fig. 2 Pooling results of the ACD group and the CLT group. The results were shown as follows: re-herniation rate, reoperation rate and severe adverse event rate

analyses showed that significant differences were found in the rate of re-herniation (ACD: 10.73%, CTL: 21.27%) and reoperation (ACD: 4.96%, CTL: 13.82%) at 24 months after LLD. The findings of this study suggested that the implantation of ACD was associated with lower re-herniation and reoperation rate specially for patients underwent LLD. And high-quality RCTs with sufficiently large sample sizes evaluating effect of ACD implantation in different methods of discectomy are needed in the future.

No significant difference was found in VAS-back, VAS-leg, ODI and SF-12 PCS between ACD group and CTL group in our study. Whereas, the comparison of ODI between ACD and CTL existed a high statistical heterogeneity ( $I^2 = 52\%$ ). The number of participations in Cho's trial was lower compared to other included trials. Moreover, about 70% participations in Cho's trial was available at 2-year follow-up, which might limit the veracity of their

conclusions of long-term outcome. Hence, we performed a sensitivity analysis when analyzing ODI. After omitting Cho's study, there was no statistical heterogeneity found  $(I^2 = 0\%)$  and the result was not affected. These findings in this study indicated that the implantation of ACD did not affect the clinical outcomes, such as pain relief and disability recovery after lumbar discectomy in 2-year follow-up. However, a few clinical trials held different opinions. Kienzler et al. and Nanda et al. [17, 19] suggested that addition of a bone-anchored ACD in lumbar discectomy was associated with better long-term (over 3 or 4 years after surgery) pain and disability relief compared to discectomy alone. Bouma et al. [16] set subgroups by age and suggested that both younger and older patients derived better benefits in clinical outcomes with bone-anchored ACD implantation compared with discectomy alone.

0.01

0.1

10

WITH ACD WITHOUT ACD

100

WITH ACD		WITHOUT ACD			Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
VAS LEG									
Bailey 2013	1.5	2.79	478	1.7	3.22	249	96.7%	-0.20 [-0.67, 0.27]	_
Barth 2018	2	20.75	242	3	23.25	251	1.4%	-1.00 [-4.89, 2.89]	
Cho 2019	16	20	30	12	18	30	0.2%	4.00 [-5.63, 13.63]	
Thomé 2018	12	21	252	14	21	252	1.6%	-2.00 [-5.67, 1.67]	<u>+</u> -
Subtotal (95% CI)			1002			782	100.0%	-0.23 [-0.69, 0.23]	
Heterogeneity: $Chi^2 = 1$	.80, df =	3(P = 0)	0.61); l <sup>a</sup>	2 = 0%					
	2 - 0.97	(= - 0.5	.5)						
VAS BACK									
Bailey 2013	2.2	2.79	478	2.3	3.22	249	97.1%	-0.10 [-0.57, 0.37]	
Barth 2018	9	22.5	242	12	23.5	251	1.3%	-3.00 [-7.06, 1.06]	-
Cho 2019	20	18	30	16	18	30	0.3%	4.00 [-5.11, 13.11]	
Thome 2018	18	23	252	19	24	252	1.3%	-1.00 [-5.10, 3.10]	
Subtotal (95% CI)	00.10	0 (D	1002	0.00		782	100.0%	-0.14 [-0.60, 0.33]	
Heterogeneity: $Chi^2 = 2$ Test for overall effect: 2	2.90, af = Z = 0.59	3(P = 0.5)	0.41); I <sup>.</sup> 6)	- = 0%					
		(	- /						
SF-12 PCS							/		
Bailey 2013	46.5	13.96	478	46.7	13.28	249	55.0%	-0.20 [-2.27, 1.87]	1
Cho 2019	26	5	30	27	4	30	45.0%	-1.00 [-3.29, 1.29]	
Subtotal (95% CI)			508			279	100.0%	-0.56 [-2.10, 0.98]	Y
Heterogeneity: Chi <sup>2</sup> = 0	1.26, df =	1 (P = (	0.61); I <sup>2</sup>	= 0%					
l est for overall effect: A	2 = 0.71	(P = 0.4	8)						
Surgical Time									_
Barth 2018	69.7	31.5	242	51.4	25.2	251	83.5%	18.30 [13.25, 23.35]	
Cho 2019	143.33	21.43	30	126.17	23.37	30	16.5%	17.16 [5.81, 28.51]	
Subtotal (95% CI)			272			281	100.0%	18.11 [13.50, 22.72]	
Heterogeneity: Chi <sup>2</sup> = 0	).03, df =	1 (P = 0	0.86); l²	² = 0%					
Test for overall effect: Z = 7.70 (P < 0.00001)									
	14/1			VALITI		<b>CD</b>		Maan Difference	Maan Difference
Study or Subaroup	Moon		J	Moon		Total	Woight	Wean Difference	Wean Difference
	Weall	30	Total	Weall	30	Total	weight		
Bailov 2012	20.0	26.24	170	20	22.25	240	22 00/	0 00 [ 2 92 4 62]	
Dalley 2013	20.9	17 5	4/0	20	23.35	249	22.0%	0.90 [-2.03, 4.03]	
Cho 2010	0 10	17.5	242	9	19.5	201	20.0%	- 1.00 [-4.27, 2.27]	
Cho 2019	10	11	30	14	15	30	19.3%	5.00 [0.00, 9.32]	
Subtotal (95% CI)	13	14	1002	14	15	782	100 0%	- 1.00 [-3.55, 1.55] 0 50 [-1 85, 3 03]	
Heterogeneity: $Tau^2 = 3.19$ : $Chi^2 = 6.25$ , $df = 3.(P = 0.10)$ ; $l^2 = 52\%$									
Test for overall effect $7 = 0.47$ (P = 0.64)									
	2 - 0.47	(1 - 0.0	(+)						
									-10 -5 0 5 10
									WITH ACD WITHOUT ACD

Fig. 3 Pooling results of the ACD group and the CLT group. The results were shown as follows: VAS-leg, VAS-back, SF-12 PCS, surgical time and ODI

The surgical time of ACD group was longer than CTL group with statistical significance in this study. The prolonged surgical time is associated with complications such as surgical site infection and it is a universal goal for surgeons to decreased surgical time continuously [29–31]. The introduction of a new technique into presenting surgery always requires surgeon to gain experience and overcome a learning curve to decrease the surgical time. Therefore, it is important for surgeon to weigh if the increase in surgical time caused by a new technique could be justified by the benefits it provides. The methods on reducing the additional surgical time for ACD implantation needs further research in the future.

Vertebral endplate changes (VEPC) are common in lumbar spine and could be classified as Schmorl's nodes, fracture, erosion, or calcification [32]. Brayda-Bruno et al. [33] reported that the "notched" and "Schmorl's nodes" were the most common classification of VEPC, and VEPC was found to be associated with disc degeneration and signal alterations on MRI. Moreover, Feng et al. [34] suggested that cartilaginous endplate avulsion could be associated with residual pain after lumbar discectomy. The study of Zehra et al. [35]

Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI		WITH A	CD	WITHOUT	ACD		Odds Ratio	Odds Ratio	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl	
Cho 2019 1 30 6 30 5.8% 0.14 [0.02, 1.23] Thomé 2018 31 250 65 257 56.1% 0.42 [0.26, 0.67] Subtotal (95% CI) 522 536 100.0% 0.44 [0.31, 0.63] Total events 56 114 Heterogeneity: Ch <sup>2</sup> = 1.56, df = 2 ( $P = 0.46$ ); $P = 0\%$ Test for overall effect: $Z = 4.60 (P < 0.00001)$ Reoperation Cho 2019 1 30 6 30 8.0% 0.14 [0.02, 1.23] Kursumovic 2018 12 242 34 249 44.0% 0.33 [0.17, 0.65] Thomé 2018 14 272 37 278 48.0% 0.33 [0.21, 0.67] Subtotal (95% CI) 544 557 100.0% 0.33 [0.21, 0.67] Subtotal (95% CI) 544 557 100.0% 0.33 [0.21, 0.67] Total events 27 77 Heterogeneity: Ch <sup>2</sup> = 0.66, df = 2 ( $P = 0.72$ ); $P = 0\%$ Test for overall effect: $Z = 4.46 (P < 0.00001)$ Vertebral Endplate Changes Kursumovic 2018 12 242 24 249 49.4% 0.37 [0.21, 0.67] Subtotal (95% CI) 514 527 100.0% 0.40 [0.27, 0.60] Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Vale vents 456 178 Heterogeneity: Ch <sup>2</sup> = 0.60, df = 1 ( $P = 0.80$ ; $P = 0\%$ Test for overall effect: $Z = 16.48$ ( $P < 0.00001$ )	Re-nerniation		00	0		5.00/	0.4450.00.4.001		
Kursumovic 2018 $24$ $242$ $43$ $249$ $36.1\%$ $0.55$ $(0.13, 0.50)$ Thomé 2018 $31$ $250$ $65$ $257$ $56.1\%$ $0.42$ $0.26.0.67$ Subtotal (95% Cl) $522$ $536$ $100.0\%$ $0.44$ $(0.31, 0.63)$ Total events $56$ $114$ Heterogeneity: Ch <sup>2</sup> = 1.66, df = 2 (P = 0.46); P = 0%         Test for overall effect: Z = 4.60 (P < 0.00001)         Reoperation         Cho 2019       1 $30$ $6$ $30$ $8.0\%$ $0.14$ [0.02, 1.23]         Thomé 2018       12 $242$ $34$ $249$ $44.0\%$ $0.33$ [0.17, 0.67]         Subtotal (95% Cl)       544       557       100.0% $0.33$ [0.21, 0.67] $\bullet$ Heterogeneity: Ch <sup>2</sup> = 0.66, df = 2 (P = 0.72); P = 0%       Test for overall effect: Z = 4.83 (P < 0.00001) $\bullet$ $\bullet$ $\bullet$ $\bullet$ Subtotal (95% Cl)       514       527       100.0% $0.37$ [0.21, 0.67] $\bullet$ $\bullet$ Thomé 2018       21       272       278       48.0% $0.37$ [0.21, 0.67] $\bullet$ Subtotal (95% Cl) </td <td>Cho 2019</td> <td>1</td> <td>30</td> <td>6</td> <td>30</td> <td>5.8%</td> <td>0.14 [0.02, 1.23]</td> <td>-</td>	Cho 2019	1	30	6	30	5.8%	0.14 [0.02, 1.23]	-	
In the 2018 31 250 65 257 96.1% 0.42 [0.26, 0.67] Subtotal (95% Cl) 522 536 100.0% 0.44 [0.31, 0.63] Total events 56 114 Heterogeneity: Ch <sup>2</sup> = 1.56, df = 2 (P = 0.46); P = 0% Test for overall effect: Z = 4.60 (P < 0.00001) Reoperation Cho 2019 1 30 6 30 8.0% 0.14 [0.02, 1.23] Kursumovic 2018 12 242 34 249 44.0% 0.33 [0.17, 0.65] Thomé 2018 14 272 37 278 48.0% 0.35 [0.19, 0.67] Subtotal (95% Cl) 544 557 100.0% 0.33 [0.21, 0.51] Total events 27 77 Heterogeneity: Ch <sup>2</sup> = 0.66, df = 2 (P = 0.72); P = 0% Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% Cl) 514 527 100.0% 0.40 [0.27, 0.60] Heterogeneity: Ch <sup>2</sup> = 0.13, df = 1 (P = 0.72); P = 0% Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Ch <sup>2</sup> = 0.66, df = 1 (P = 0.80); P = 0% Test for overall effect: Z = 16.48 (P < 0.00001) 0.01 0.1 1 10	Kursumovic 2018	24	242	43	249	38.1%	0.53 [0.31, 0.90]		
Subtotal (95% CI) 522 358 100.0% 0.44 [0.31, 0.63] Total events 56 114 Heterogeneity: Chi <sup>2</sup> = 1.56, df = 2 (P = 0.46); P = 0% Test for overall effect: Z = 4.60 (P < 0.00001) Reoperation Cho 2019 1 30 6 30 8.0% 0.14 [0.02, 1.23] Kursumovic 2018 12 242 34 249 44.0% 0.33 [0.17, 0.65] Thomé 2018 14 272 37 278 48.0% 0.35 [0.19, 0.67] Subtotal (95% CI) 544 557 100.0% 0.33 [0.21, 0.51] Total events 27 77 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); P = 0% Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% CI) 514 527 100.0% 0.40 [0.27, 0.60] Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 533 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 1 (P = 0.80); P = 0% Test for overall effect: Z = 16.48 (P < 0.00001) 0.01 0.1 1 100	Finome 2018	31	250	65	257	56.1%	0.42 [0.26, 0.67]	<b>—</b>	
Total events $39$ $89$ Heterogeneity: Ch <sup>2</sup> = 1.56, df = 2 (P = 0.46); P = 0% Test for overall effect: Z = 4.60 (P < 0.00001) Reoperation Cho 2019 1 30 6 30 8.0% 0.14 [0.02, 1.23] Kursumovic 2018 12 242 34 249 44.0% 0.33 [0.17, 0.65] Thomé 2018 14 272 37 278 48.0% 0.35 [0.19, 0.67] Subtotal (95% Cl) 544 557 100.0% 0.33 [0.21, 0.67] Total events 27 77 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); P = 0% Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 12 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% Cl) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); P = 0% Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); P = 0% Test for overall effect: Z = 16.48 (P < 0.00001) Use the constant of th	Subiolal (95% CI)	50	522	444	530	100.0%	0.44 [0.31, 0.63]	•	
The derivage intervention of the second state	Lotaregeneity Chi2 = 1		0 (D – C	114					
Resperation         Cho 2019       1       30       8.0%       0.14 [0.02, 1.23]         Kursumovic 2018       12       242       34       2.49       44.0%       0.33 [0.17, 0.65]         Thomé 2018       14       27       77         Reterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); l <sup>2</sup> = 0%         Test for overall effect: Z = 4.83 (P < 0.00001)         Serious Adverse Events         Kursumovic 2018       18       242       44       249       49.4%       0.37 [0.21, 0.67]         Thomé 2018       21       272       45       278       50.6%       0.43 [0.25, 0.75]         Subtotal (95% Cl)       514       527       100.0%       0.40 [0.27, 0.60]         Vertebral Endplate Changes       Kursumovic 2018       227       267       94       283       51.0%       11.41 [7.52, 17.32]         Thomé 2018 <th colspa<="" td=""><td>Test for everall effect: T</td><td>.30, ui = /</td><td>2 (P = 0</td><td>7.40); I<sup>-</sup> = 0%</td><td>D</td><td></td><td></td><td></td></th>	<td>Test for everall effect: T</td> <td>.30, ui = /</td> <td>2 (P = 0</td> <td>7.40); I<sup>-</sup> = 0%</td> <td>D</td> <td></td> <td></td> <td></td>	Test for everall effect: T	.30, ui = /	2 (P = 0	7.40); I <sup>-</sup> = 0%	D			
Reoperation         Cho 2019       1       30       6       30       8.0%       0.14 [0.02, 1.23]         Kursumovic 2018       12       242       34       44.0%       0.33 [0.17, 0.65]         Thomé 2018       14       27       77         Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72);   <sup>2</sup> = 0%         Total events       27       77         Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72);   <sup>2</sup> = 0%         Test for overall effect: Z = 4.83 (P < 0.00001)         Serious Adverse Events         Kursumovic 2018       18       242       44       249       49.4%       0.37 [0.21, 0.67]         Thomé 2018       21       272       45       27       7         Subtotal (95% Cl)       514       527       100.0%       0.43 [0.25, 0.75]       Image: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72);   <sup>2</sup> = 0%       Test for overall effect: Z = 4.46 (P < 0.00001)       Vertebral Endpla	rest for overall effect. 2	2 – 4.00 (1	- < 0.00	JUUT)					
Cho 2019 1 30 6 30 8.0% 0.14 [0.02, 1.23] Kursumovic 2018 12 242 34 249 44.0% 0.35 [0.17, 0.65] Thomé 2018 14 272 37 278 48.0% 0.35 [0.19, 0.67] Subtotal (95% CI) 544 557 100.0% 0.33 [0.21, 0.67] Total events 27 77 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% CI) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0% Test for overall effect: Z = 16.48 (P < 0.00001)	Reoperation								
Kursumovic 2018       12       242       34       249       44.0% $0.33 [0.17, 0.65]$ Thomé 2018       14       272       37       278       48.0% $0.35 [0.19, 0.67]$ Subtotal (95% CI)       544       557       100.0% $0.33 [0.21, 0.51]$ Total events       27       77         Heterogeneity: Chi² = 0.66, df = 2 (P = 0.72); l² = 0%       Serious Adverse Events         Kursumovic 2018       18       242       44       249       49.4% $0.37 [0.21, 0.67]$ Thomé 2018       21       272       45       278       50.6% $0.43 [0.25, 0.75]$ Subtotal (95% CI)       514       527       100.0% $0.40 [0.27, 0.60]$ Total events       39       89         Heterogeneity: Chi² = 0.13, df = 1 (P = 0.72); l² = 0%         Test for overall effect: Z = 4.46 (P < 0.00001)	Cho 2019	1	30	6	30	8.0%	0.14 [0.02, 1.23]		
Thomé 2018 14 272 37 278 48.0% $0.35 [0.19, 0.67]$ Subtotal (95% CI) 544 557 100.0% $0.33 [0.21, 0.51]$ Total events 27 77 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% $0.37 [0.21, 0.67]$ Thomé 2018 21 272 45 278 50.6% $0.43 [0.25, 0.75]$ Subtotal (95% CI) 514 527 100.0% $0.40 [0.27, 0.60]$ Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0% Test for overall effect: Z = 16.48 (P < 0.00001)	Kursumovic 2018	12	242	34	249	44.0%	0.33 [0.17, 0.65]		
Subtotal (95% Cl) 544 557 100.0% 0.33 [0.21, 0.51] Total events 27 77 Heterogeneity: Chi <sup>2</sup> = 0.66, df = 2 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: $Z = 4.83$ (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% Cl) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: $Z = 4.46$ (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.6.48$ (P < 0.00001)	Thomé 2018	14	272	37	278	48.0%	0.35 [0.19, 0.67]		
Total events 27 77 Heterogeneity: $Chi^2 = 0.66$ , $df = 2$ (P = 0.72); $i^2 = 0\%$ Test for overall effect: Z = 4.83 (P < 0.00001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% Cl) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: $Chi^2 = 0.13$ , $df = 1$ (P = 0.72); $i^2 = 0\%$ Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: $Chi^2 = 0.06$ , $df = 1$ (P = 0.80); $i^2 = 0\%$ Test for overall effect: Z = 16.48 (P < 0.00001)	Subtotal (95% CI)		544		557	100.0%	0.33 [0.21, 0.51]	•	
Heterogeneity: $Chi^2 = 0.66$ , $df = 2 (P = 0.72)$ ; $l^2 = 0\%$ Test for overall effect: $Z = 4.83 (P < 0.00001)$ Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% CI) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: $Chi^2 = 0.13$ , $df = 1 (P = 0.72)$ ; $l^2 = 0\%$ Test for overall effect: $Z = 4.46 (P < 0.00001)$ Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: $Chi^2 = 0.06$ , $df = 1 (P = 0.80)$ ; $l^2 = 0\%$ Test for overall effect: $Z = 16.48 (P < 0.00001)$	Total events	27		77					
Test for overall effect: $Z = 4.83$ (P < 0.0001) Serious Adverse Events Kursumovic 2018 18 242 44 249 49.4% 0.37 [0.21, 0.67] Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% CI) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: $Z = 4.46$ (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% CI) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0% Test for overall effect: $Z = 16.48$ (P < 0.00001)	Heterogeneity: Chi <sup>2</sup> = 0	.66, df = 2	2 (P = 0	0.72); I <sup>2</sup> = 0%	, D				
Serious Adverse Events         Kursumovic 2018       18       242       44       249       49.4% $0.37 [0.21, 0.67]$ Thomé 2018       21       272       45       278       50.6% $0.43 [0.25, 0.75]$ Subtotal (95% Cl)       514       527       100.0% $0.40 [0.27, 0.60]$ Total events       39       89         Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0%       78       50.6%       11.41 [7.52, 17.32]         Test for overall effect: Z = 4.46 (P < 0.00001)       11.41 [7.52, 17.32]       100.0%       11.85 [8.83, 15.90]         Numé 2018       229       272       84       278       49.0%       12.30 [8.13, 18.61]         Subtotal (95% Cl)       539       561       100.0%       11.85 [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%       11.85 [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%       10.00001         0.01       0.1       10	Test for overall effect: 2	z = 4.83 (I	P < 0.00	0001)					
Kursumovic 2018       18       242       44       249       49.4%       0.37 [0.21, 0.67]         Thomé 2018       21       272       45       278       50.6%       0.43 [0.25, 0.75]         Subtotal (95% Cl)       514       527       100.0%       0.40 [0.27, 0.60]         Total events       39       89         Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0%       283       51.0%       11.41 [7.52, 17.32]         Vertebral Endplate Changes       Kursumovic 2018       227       267       94       283       51.0%       11.41 [7.52, 17.32]         Thomé 2018       229       272       84       278       49.0%       12.30 [8.13, 18.61] $\bullet$ Subtotal (95% Cl)       539       561       100.0%       11.85 [8.83, 15.90] $\bullet$ Total events       456       178       11.85 [8.83, 15.90] $\bullet$ $\bullet$ Test for overall effect: Z = 16.48 (P < 0.00001) $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ Up the events       456       178 $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ Up the events       0.01       0.1       10       100       100<	Serious Adverse	Events							
Thomé 2018 21 272 45 278 50.6% 0.43 [0.25, 0.75] Subtotal (95% Cl) 514 527 100.0% 0.40 [0.27, 0.60] Total events 39 89 Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0% Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0% Test for overall effect: Z = 16.48 (P < 0.00001)	Kursumovic 2018	18	242	44	249	49 4%	0 37 [0 21 0 67]		
Subtotal (95% Cl)       514       527       100.0%       0.40 [0.27, 0.60]         Total events       39       89         Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0%         Test for overall effect: $Z = 4.46$ (P < 0.00001)	Thomé 2018	21	272	45	278	50.6%	0.43 [0.25, 0.75]		
Total events       39       89         Heterogeneity: Chi <sup>2</sup> = 0.13, df = 1 (P = 0.72); l <sup>2</sup> = 0%         Test for overall effect: Z = 4.46 (P < 0.00001)	Subtotal (95% CI)	21	514	40	527	100.0%	0.40 [0.27, 0.60]	$\bullet$	
Heterogeneity: $Chi^2 = 0.13$ , $df = 1$ (P = 0.72); $l^2 = 0\%$ Test for overall effect: Z = 4.46 (P < 0.00001) Vertebral Endplate Changes Kursumovic 2018 227 267 94 283 51.0% 11.41 [7.52, 17.32] Thomé 2018 229 272 84 278 49.0% 12.30 [8.13, 18.61] Subtotal (95% Cl) 539 561 100.0% 11.85 [8.83, 15.90] Total events 456 178 Heterogeneity: $Chi^2 = 0.06$ , $df = 1$ (P = 0.80); $l^2 = 0\%$ Test for overall effect: Z = 16.48 (P < 0.00001)	Total events	39		89			. / .		
Test for overall effect: Z = 4.46 (P < 0.00001)	Heterogeneity: $Chi^2 = 0.13$ , $df = 1$ (P = 0.72); $l^2 = 0\%$								
Vertebral Endplate Changes         Kursumovic 2018       227       267       94       283       51.0%       11.41 [7.52, 17.32]         Thomé 2018       229       272       84       278       49.0%       12.30 [8.13, 18.61]         Subtotal (95% CI)       539       561       100.0%       11.85 [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%	Test for overall effect: $Z = 4.46$ (P < 0.00001)								
Vertebral Endplate Changes         Kursumovic 2018       227       267       94       283       51.0%       11.41       [7.52, 17.32]         Thomé 2018       229       272       84       278       49.0%       12.30       [8.13, 18.61]         Subtotal (95% CI)       539       561       100.0%       11.85       [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%       7         Test for overall effect: Z = 16.48 (P < 0.00001)       0.01       0.1       1       10       100									
Kursumovic 2018       227       267       94       283       51.0%       11.41 [7.52, 17.32]         Thomé 2018       229       272       84       278       49.0%       12.30 [8.13, 18.61]         Subtotal (95% CI)       539       561       100.0%       11.85 [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%         Test for overall effect: Z = 16.48 (P < 0.00001)			jes	0.4	000	F4 00/	44 44 17 50 47 001		
Inome 2018       229       272       84       278       49.0%       12.30 [8.13, 18.61]         Subtotal (95% CI)       539       561       100.0%       11.85 [8.83, 15.90]         Total events       456       178         Heterogeneity: Chi <sup>2</sup> = 0.06, df = 1 (P = 0.80); l <sup>2</sup> = 0%       Test for overall effect: Z = 16.48 (P < 0.00001) $0.01$ $0.1$ $1$ $10$ $100$	Kursumovic 2018	227	267	94	283	51.0%	11.41 [7.52, 17.32]		
$\begin{array}{c} \text{Subtotal (55.% Cl)} & \text{SSS} &$	I nome 2018 Subtotal (95% CI)	229	272	84	278	49.0%	12.30 [8.13, 18.61]	<b>→</b>	
Heterogeneity: $Chi^2 = 0.06$ , $df = 1$ (P = 0.80); $l^2 = 0\%$ Test for overall effect: Z = 16.48 (P < 0.00001)	Total overts	156	555	179	501	100.070	11.00 [0.00, 10.00]	•	
Test for overall effect: $Z = 16.48$ (P < 0.00001) 0.01 0.1 1 10 100	Heterogeneity: $Chi^2 = 0.06 df = 1 (P = 0.80); l^2 = 0\%$								
	Test for overall effect: $Z = 16.48$ (P < 0.0001)								
		_ 10.40	(, · · 0.)						
0.01 0.1 1 10 100									

Fig. 4 Pooling results of subgroup analyses based on surgery type. The results were shown as follows: re-herniation rate, reoperation rate, severe adverse event rate and vertebral endplate changes

also noted that increased endplate defect was directly associated with facet joint changes, leading to pain. The VEPC of ACD group were superior to CTL group at 24 months after LLD in this presenting study. Whereas, VEPC had no impact on SAE rate and various clinical outcomes such as ODI, VAS and SF-12 PCS based on our results. Future studies should focus on long-term follow-up and evaluate the longterm effect of VEPC after ACD implantation on surgical outcomes.

At present, Barricaid<sup>TM</sup> is the most popular annular closing device on the market. The Xclose device is no longer available right now, and there is other solution called AnchorKnot® used in some centers [36, 37]. Ament et al. performed a cost-effectiveness analysis of ACD implantation for lumbar discectomy in 2019 [38]. They suggested that the ACD implantation was highly cost-effective compared to lumbar discectomy alone at 2 years after surgery for LDH patients with large postoperative annular defects ( $\geq 6$  mm). According to its effect and prolonged surgical time, we suggested that ACD implantation should be treated with caution. As the results shown in this presenting study, there is currently no strong evidence suggesting that discectomy with ACD implantation is economically favorable and surgically safer compared to standard discectomy. At present, the subgroup suitable for ACD implantation could be LDH patients undergoing LLD with large annular defects ( $\geq 6$  mm).

The objective of this study was to systematically estimate the effectiveness and safety of ACD implantation in lumbar discectomy for patients with LDH. There were two studies based on fewer number and mixed clinical trials (randomized or non-randomized) on similar topic with low credibility [39, 40]. In this meta-analysis, we recruited five RCTs which performed the comparison between ACD and CTL

#### Fig. 5 Risk of bias summary



Other bias

after discectomy, including 2380 patients (1289 in ACD group and 1091 in CTL group). Moreover, subgroup analyses were performed based on the surgery type to compare the effect of ACD implantation between surgical techniques more precisely. Whereas, there were still several limitations in this study. First, the cost-effectiveness of ACD implantation in discectomy for patients with LDH was not available in the included trials. Second, clear allocation concealment was not presented in some included trials.

# Conclusion

Discectomy either with or without ACD implantation is considered to achieve similar clinical outcomes. Whereas, the ACD implantation in LLD is associated with lower reherniation and reoperation rate but prolonged surgical time for LDH patients. We suggested that ACD implantation should be treated with caution. More independently highquality RCTs with sufficiently large sample sizes reporting cost-effectiveness and evaluating the effect of ACD implantation in different discectomy are needed.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00586-023-07629-0.

Acknowledgements This study was supported by National Natural Science Foundation of China (NO: 81871803). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Declarations

**Conflict of interests** The authors have no conflict of interest to disclose.

## References

 Mixter WJ, Barr JS (1934) Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 211:210–215. https://doi.org/10.1056/nejm193408022110506

- Kim SK, Kang SS, Hong YH, Park SW, Lee SC (2018) Clinical comparison of unilateral biportal endoscopic technique versus open microdiscectomy for single-level lumbar discectomy: a multicenter, retrospective analysis. J Orthop Surg Res 13:22. https://doi.org/10.1186/s13018-018-0725-1
- Mayer HM, Brock M, Berlien HP, Weber B (1992) Percutaneous endoscopic laser discectomy (PELD). A new surgical technique for non-sequestrated lumbar discs. Acta Neurochir Suppl (Wien) 54:53–58. https://doi.org/10.1007/978-3-7091-6687-1\_7
- Foley KT, Smith MM, Rampersaud YR (1999) Microendoscopic approach to far-lateral lumbar disc herniation. Neurosurg Focus 7:e5. https://doi.org/10.3171/foc.1999.7.6.6
- Ruetten S, Komp M, Godolias G (2005) An extreme lateral access for the surgery of lumbar disc herniations inside the spinal canal using the full-endoscopic uniportal transforaminal approach-technique and prospective results of 463 patients. Spine (Phila Pa 1976) 30:2570–2578. https://doi.org/10.1097/ 01.brs.0000186327.21435.cc
- Yeung AT, Tsou PM (2002) Posterolateral endoscopic excision for lumbar disc herniation: surgical technique, outcome, and complications in 307 consecutive cases. Spine (Phila Pa 1976) 27:722–731. https://doi.org/10.1097/00007632-20020 4010-00009
- Cheng J, Wang H, Zheng W, Li C, Wang J, Zhang Z, Huang B, Zhou Y (2013) Reoperation after lumbar disc surgery in two hundred and seven patients. Int Orthop 37:1511–1517. https://doi.org/ 10.1007/s00264-013-1925-2
- Heindel P, Tuchman A, Hsieh PC, Pham MH, D'Oro A, Patel NN, Jakoi AM, Hah R, Liu JC, Buser Z, Wang JC (2017) Reoperation rates after single-level lumbar discectomy. Spine (Phila Pa 1976) 42:E496-e501. https://doi.org/10.1097/brs.000000000001855
- Ambrossi GL, McGirt MJ, Sciubba DM, Witham TF, Wolinsky JP, Gokaslan ZL, Long DM (2009) Recurrent lumbar disc herniation after single-level lumbar discectomy: incidence and health care cost analysis. Neurosurgery 65:574–578. https://doi.org/10. 1227/01.Neu.0000350224.36213.F9
- Adogwa O, Parker SL, Shau DN, Mendenhall SK, Aaronson O, Cheng JS, Devin CJ, McGirt MJ (2012) Cost per quality-adjusted life year gained of revision neural decompression and instrumented fusion for same-level recurrent lumbar stenosis: defining the value of surgical intervention. J Neurosurg Spine 16:135–140. https://doi.org/10.3171/2011.9.Spine11308
- Aihara T, Endo K, Sawaji Y, Suzuki H, Urushibara M, Kojima A, Matsuoka Y, Takamatsu T, Murata K, Kusakabe T, Maekawa A, Yamamoto K (2020) Five-year reoperation rates and causes for reoperations following lumbar microendoscopic discectomy and decompression. Spine (Phila Pa 1976) 45:71–77. https://doi.org/ 10.1097/brs.000000000003206
- Carragee EJ, Han MY, Suen PW, Kim D (2003) Clinical outcomes after lumbar discectomy for sciatica: the effects of fragment type and anular competence. J Bone Joint Surg Am 85:102–108
- Miller LE, McGirt MJ, Garfin SR, Bono CM (2018) Association of annular defect width after lumbar discectomy with risk of symptom recurrence and reoperation: systematic review and meta-analysis of comparative studies. Spine (Phila Pa 1976) 43:E308-e315. https://doi.org/10.1097/brs.00000000002501
- Bailey A, Araghi A, Blumenthal S, Huffmon GV (2013) Prospective, multicenter, randomized, controlled study of anular repair in lumbar discectomy: two-year follow-up. Spine (Phila Pa 1976) 38:1161–1169. https://doi.org/10.1097/BRS.0b013e31828b2e2f
- Klassen PD, Bernstein DT, Köhler HP, Arts MP, Weiner B, Miller LE, Thomé C (2017) Bone-anchored annular closure following lumbar discectomy reduces risk of complications and reoperations within 90 days of discharge. J Pain Res 10:2047–2055. https://doi. org/10.2147/jpr.S144500

- Bouma GJ, Ardeshiri A, Miller LE, Van de Kelft E, Bostelmann R, Klassen PD, Flüh C, Kuršumović A (2019) Clinical performance of a bone-anchored annular closure device in older adults. Clin Interv Aging 14:1085–1094. https://doi.org/10.2147/cia. S208098
- Nanda D, Arts MP, Miller LE, Köhler HP, Perrin JM, Flüh C, Vajkoczy P (2019) Annular closure device lowers reoperation risk 4 years after lumbar discectomy. Med Devices (Auckl) 12:327– 335. https://doi.org/10.2147/mder.S220151
- Kienzler JC, Fandino J, Van de Kelft E, Eustacchio S, Bouma GJ (2021) Risk factors for early reherniation after lumbar discectomy with or without annular closure: results of a multicenter randomized controlled study. Acta Neurochir (Wien) 163:259–268. https://doi.org/10.1007/s00701-020-04505-4
- Kienzler JC, Klassen PD, Miller LE, Assaker R, Heidecke V, Fröhlich S, Thomé C (2019) Three-year results from a randomized trial of lumbar discectomy with annulus fibrosus occlusion in patients at high risk for reherniation. Acta Neurochir (Wien) 161:1389–1396. https://doi.org/10.1007/s00701-019-03948-8
- van den Brink W, Flüh C, Miller LE, Klassen PD, Bostelmann R (2019) Lumbar disc reherniation prevention with a bone-anchored annular closure device: 1-year results of a randomized trial. Medicine (Baltimore) 98:e17760. https://doi.org/10.1097/md.00000 00000017760
- Barth M, Weiß C, Bouma GJ, Bostelmann R, Kursumovic A, Fandino J, Thomé C (2018) Endplate changes after lumbar discectomy with and without implantation of an annular closure device. Acta Neurochir (Wien) 160:855–862. https://doi.org/10.1007/ s00701-017-3463-y
- Cho PG, Shin DA, Park SH, Ji GY (2019) Efficacy of a novel annular closure device after lumbar discectomy in Korean patients : a 24-month follow-up of a randomized controlled trial. J Korean Neurosurg Soc 62:691–699. https://doi.org/10.3340/jkns. 2019.0071
- Kuršumović A, Kienzler JC, Bouma GJ, Bostelmann R, Heggeness M, Thomé C, Miller LE, Barth M (2018) Morphology and clinical relevance of vertebral endplate changes following limited lumbar discectomy with or without bone-anchored annular closure. Spine (Phila Pa 1976) 43:1386–1394. https://doi.org/10.1097/brs.00000000002632
- 24. Thomé C, Klassen PD, Bouma GJ, Kuršumović A, Fandino J, Barth M, Arts M, van den Brink W, Bostelmann R, Hegewald A, Heidecke V, Vajkoczy P, Fröhlich S, Wolfs J, Assaker R, Van de Kelft E, Köhler HP, Jadik S, Eustacchio S, Hes R, Martens F (2018) Annular closure in lumbar microdiscectomy for prevention of reherniation: a randomized clinical trial. Spine J 18:2278–2287. https://doi.org/10.1016/j.spinee.2018.05.003
- O'Connell JE (1951) Protrusions of the lumbar intervertebral discs, a clinical review based on five hundred cases treated by excision of the protrusion. J Bone Joint Surg Br 33-b:8–30. https:// doi.org/10.1302/0301-620x.33b1.8
- Williams RW (1978) Microlumbar discectomy: a conservative surgical approach to the virgin herniated lumbar disc. Spine (Phila Pa 1976) 3:175–182
- Spengler DM (1982) Lumbar discectomy. Results with limited disc excision and selective foraminotomy. Spine (Phila Pa 1976) 7:604–607
- McGirt MJ, Ambrossi GL, Datoo G, Sciubba DM, Witham TF, Wolinsky JP, Gokaslan ZL, Bydon A (2009) Recurrent disc herniation and long-term back pain after primary lumbar discectomy: review of outcomes reported for limited versus aggressive disc removal. Neurosurgery 64:338–344. https://doi.org/10.1227/01. Neu.0000337574.58662.E2
- Cheng H, Chen BP, Soleas IM, Ferko NC, Cameron CG, Hinoul P (2017) Prolonged operative duration increases risk of surgical

site infections: a systematic review. Surg Infect (Larchmt) 18:722–735. https://doi.org/10.1089/sur.2017.089

- Cheng H, Clymer JW, Po-Han Chen B, Sadeghirad B, Ferko NC, Cameron CG, Hinoul P (2018) Prolonged operative duration is associated with complications: a systematic review and metaanalysis. J Surg Res 229:134–144. https://doi.org/10.1016/j.jss. 2018.03.022
- Held MB, Boddapati V, Sarpong NO, Cooper HJ, Shah RP, Geller JA (2021) operative duration and short-term postoperative complications after unicompartmental knee arthroplasty. J Arthroplast 36:905–909. https://doi.org/10.1016/j.arth.2020.09.007
- Wang Y, Videman T, Battié MC (2012) Lumbar vertebral endplate lesions: prevalence, classification, and association with age. Spine (Phila Pa 1976) 37:1432–1439. https://doi.org/10.1097/BRS. 0b013e31824dd20a
- 33. Brayda-Bruno M, Albano D, Cannella G, Galbusera F, Zerbi A (2018) Endplate lesions in the lumbar spine: a novel MRI-based classification scheme and epidemiology in low back pain patients. Eur Spine J 27:2854–2861. https://doi.org/10.1007/s00586-018-5787-6
- Feng ZY, Hu XJ, Zheng QQ, Battié MC, Chen Z, Wang Y (2021) Cartilaginous endplate avulsion is associated with modic changes and endplate defects, and residual back and leg pain following lumbar discectomy. Osteoarthr Cartil 29:707–717. https://doi.org/ 10.1016/j.joca.2021.01.010
- Zehra U, Cheung JPY, Bow C, Lu W, Samartzis D (2019) Multidimensional vertebral endplate defects are associated with disc degeneration, modic changes, facet joint abnormalities, and pain. J Orthop Res 37:1080–1089. https://doi.org/10.1002/jor.24195
- Bateman AH, Balkovec C, Akens MK, Chan AH, Harrison RD, Oakden W, Yee AJ, McGill SM (2016) Closure of the annulus

fibrosus of the intervertebral disc using a novel suture application device-in vivo porcine and ex vivo biomechanical evaluation. Spine J 16:889–895. https://doi.org/10.1016/j.spinee.2016.03.005

- Guardado AA, Baker A, Weightman A, Hoyland JA, Cooper G (2022) Lumbar intervertebral disc herniation: annular closure devices and key design requirements. Bioengineering (Basel). https://doi.org/10.3390/bioengineering9020047
- Ament J, Thaci B, Yang Z, Kulubya E, Hsu W, Bouma G, Kim KD (2019) Cost-effectiveness of a bone-anchored annular closure device versus conventional lumbar discectomy in treating lumbar disc herniations. Spine (Phila Pa 1976) 44:5–16. https://doi.org/ 10.1097/brs.00000000002746
- Choy WJ, Phan K, Diwan AD, Ong CS, Mobbs RJ (2018) Annular closure device for disc herniation: meta-analysis of clinical outcome and complications. BMC Musculoskelet Disord 19:290. https://doi.org/10.1186/s12891-018-2213-5
- 40. Miller LE, Allen RT, Duhon B, Radcliff KE (2020) Expert review with meta-analysis of randomized and nonrandomized controlled studies of Barricaid annular closure in patients at high risk for lumbar disc reherniation. Expert Rev Med Devices 17:461–469. https://doi.org/10.1080/17434440.2020.1745061

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.